Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Response to ranibizumab following tachyphylaxis to bevacizumab in a patient with radiation maculopathy following stereotactic fractionated radiotherapy for optic nerve meningioma.

Jutley G, Shona OA, Leen RC, Lee N, Olver JM, George SM.

Arch Ophthalmol. 2012 Nov;130(11):1466-70. doi: 10.1001/archophthalmol.2012.1542. No abstract available.

PMID:
23143450
2.

Tachyphylaxis and bevacizumab.

Avgikos KN, Horgan SE, Sivaraj RR, Hu K.

Ophthalmology. 2009 Sep;116(9):1831-2; author reply 1832. doi: 10.1016/j.ophtha.2009.03.040. No abstract available.

PMID:
19729101
3.

Tachyphylaxis and bevacizumab.

Ziemssen F, Neuhann IM, Voelker M.

Ophthalmology. 2009 Aug;116(8):1591-2; author reply 1592-3. doi: 10.1016/j.ophtha.2009.03.038. No abstract available.

PMID:
19651319
4.

Bevacizumab tachyphylaxis.

Falavarjani KG, Modarres M.

Ophthalmology. 2009 May;116(5):1016-7; author reply 1017. doi: 10.1016/j.ophtha.2009.01.029. No abstract available.

PMID:
19410964
5.

Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin).

Gupta A, Muecke JS.

Retina. 2008 Jul-Aug;28(7):964-8. doi: 10.1097/IAE.0b013e3181706302.

PMID:
18698298
6.

Intravitreal ranibizumab (lucentis) for whole brain radiotherapy-induced maculopathy.

Lin S, George BZ, Wilson-Holt NJ.

Clin Oncol (R Coll Radiol). 2014 Apr;26(4):236-8. doi: 10.1016/j.clon.2013.11.030. Epub 2014 Jan 21. No abstract available.

PMID:
24457150
7.

Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation.

Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D, Walsh AC, Hwang J, Sadda SR.

Br J Ophthalmol. 2012 Jan;96(1):14-20. doi: 10.1136/bjo.2011.204685. Epub 2011 Jul 26.

PMID:
21791509
8.

Treatment of steroid refractory, Gamma Knife related radiation necrosis with bevacizumab: case report and review of the literature.

Sanborn MR, Danish SF, Rosenfeld MR, O'Rourke D, Lee JY.

Clin Neurol Neurosurg. 2011 Nov;113(9):798-802. doi: 10.1016/j.clineuro.2011.08.007. Epub 2011 Sep 8. No abstract available.

PMID:
21906869
9.

Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma.

Shah SU, Shields CL, Bianciotto CG, Iturralde J, Al-Dahmash SA, Say EA, Badal J, Mashayekhi A, Shields JA.

Ophthalmology. 2014 Jan;121(1):269-75. doi: 10.1016/j.ophtha.2013.08.039. Epub 2013 Oct 15.

PMID:
24139123
10.

Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab.

Eghøj MS, Sørensen TL.

Br J Ophthalmol. 2012 Jan;96(1):21-3. doi: 10.1136/bjo.2011.203893. Epub 2011 Jul 6.

PMID:
21733918
11.

Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery.

Deibert CP, Ahluwalia MS, Sheehan JP, Link MJ, Hasegawa T, Yomo S, Feng WH, Li P, Flickinger JC, Lunsford LD, Kondziolka D.

J Neurooncol. 2013 Nov;115(2):217-23. doi: 10.1007/s11060-013-1214-3. Epub 2013 Aug 9.

PMID:
23929592
12.

Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?

Schaal S, Kaplan HJ, Tezel TH.

Ophthalmology. 2008 Dec;115(12):2199-205. doi: 10.1016/j.ophtha.2008.07.007. Epub 2008 Oct 18.

PMID:
18930553
13.

[Bevacizumab versus ranibizumab: a draw?].

Souied EH, Cohen SY, Kodjikian L.

J Fr Ophtalmol. 2012 Feb;35(2):79-81. doi: 10.1016/j.jfo.2011.06.003. Epub 2011 Oct 26. Review. French. No abstract available.

14.

[Fractionated stereotactic radiotherapy for optic nerve sheath meningioma: eight cases].

Litré CF, Noudel R, Colin P, Sherpereel B, Peruzzi P, Rousseaux P.

Neurochirurgie. 2007 Nov;53(5):333-8. Epub 2007 Aug 20. French.

PMID:
17707866
15.

[Fractionated stereotactic radiotherapy in optic nerve sheath meningioma].

Llorente-González S, Arbizu-Duralde A, Pastora-Salvador N.

Arch Soc Esp Oftalmol. 2008 Jul;83(7):441-4. Spanish.

16.

Resistance, not tachyphylaxis or tolerance.

Arjamaa O, Minn H.

Br J Ophthalmol. 2012 Aug;96(8):1153-4. doi: 10.1136/bjophthalmol-2012-301823. Epub 2012 Apr 17. No abstract available.

PMID:
22510583
17.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group.

Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.

PMID:
23916488
18.

Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.

Park SS, Daftari I, Phillips T, Morse LS.

Retina. 2012 May;32(5):956-66. doi: 10.1097/IAE.0b013e31822a8d6a.

PMID:
22183743
19.

Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.

Jackson TL, Chakravarthy U, Kaiser PK, Slakter JS, Jan E, Bandello F, O'Shaughnessy D, Gertner ME, Danielson L, Moshfeghi DM; INTREPID Study Group.

Ophthalmology. 2013 Sep;120(9):1893-900. doi: 10.1016/j.ophtha.2013.02.016. Epub 2013 Mar 13.

PMID:
23490327
20.

Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?

Binder S.

Br J Ophthalmol. 2012 Jan;96(1):1-2. doi: 10.1136/bjophthalmol-2011-301236. No abstract available.

PMID:
22157632

Supplemental Content

Support Center